Rheumatology (Oxford). 2021 Dec 17:keab931. doi: 10.1093/rheumatology/keab931. Online ahead of print.
ABSTRACT
OBJECTIVE: To examine whether early therapeutic intervention, compared with delayed intervention, is beneficial for patients with early systemic sclerosis (SSc).
METHODS: This is a single-center, retrospective cohort study of SSc patients who received cyclophosphamide, mycophenolate mofetil, methotrexate, or tocilizumab for diffuse cutaneous SSc (dcSSc) or interstitial lung disease (ILD) within 6 years after disease onset. The patients were divided into early and delayed intervention groups based on the disease duration of ≤ 18 and >18 months at treatment introduction, respectively. Clinical worsening was defined as the development of any original or revised ACR Composite Response Index in Systemic Sclerosis (CRISS) step 1 event or progressive fibrosing ILD (PF-ILD).
RESULTS: There was no difference in baseline characteristics between the early (n = 25) and delayed (n = 21) intervention groups except forced vital capacity (FVC), which was better in the early vs delayed intervention groups. The early intervention group less frequently had stable pulmonary function over one year than did the late intervention group (odds ratio 0.087, 95% confidence interval 0.0079-0.51, p = 0.003). The active disease was significantly decreased from 79% to 42% in the early intervention group (p = 0.007), but the change in the delayed intervention group was not statistically significant (68% to 42%, p = 0.11). Cumulative rates free from clinical worsening events defined by revised ACR-CRISS and PF-ILD were significantly higher in the early vs delayed intervention groups (p = 0.03 and 0.003, respectively).
CONCLUSION: A therapeutic “window of opportunity” might exist in SSc patients.
PMID:34919668 | DOI:10.1093/rheumatology/keab931
